Results 51 to 60 of about 3,132 (216)

Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1

Advanced Healthcare Materials, Volume 15, Issue 35, 18 September 2026.
A bicistronic rAAV8 vector encoding Aflibercept (Afb) and COMP‐cAng1 simultaneously coordinates VEGF clearance and Tie2‐mediated vessel maturation. In a 3D angiogenesis‐on‐a‐chip model, rAAV8‐Afb/cAng1 effectively reverses pathological barrier breakdown under clinical disease‐mimicking challenges.
Bong‐Kyu Kim, Jaehong Min, Sang‐Hee Park, Subeen Shin, Sangbin Yu, Jeong‐Eun Park, Sujin Kim, Wooju Park, Jihoon Ko, Sunjong Kwon   +9 more
wiley   +1 more source

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients

BMC Ophthalmology
Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents is the standard of care for neovascular age-related macular degeneration (nAMD), but treatment resistance and incomplete fluid resolution remain challenges in ...
Yufeng Xu, Ningxi Hong, Mingzhi Su, Weixin Zheng, Panpan Ye   +4 more
semanticscholar   +1 more source

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 6, Page 674-681, September 2026.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Faricimab for Treatment-Resistant Diabetic Macular Edema

Clinical Ophthalmology, 2022
To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF).A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts.
Ryan B Rush, Sloan W Rush
openaire   +3 more sources

Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland

BMC Health Services Research
Background This study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources.
Michał Seweryn, Justyna Kopel, Joanna Augustynska, Adam Mikołajewicz, Mario Damiano Toro, Robert Rejdak   +5 more
doaj   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
Background Faricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs ...
Chang-Zhu He, Q. Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He   +5 more
semanticscholar   +1 more source

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
ABSTRACT Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases.
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch   +10 more
wiley   +1 more source

Faricimab at 6 and 12 mg reduces pigment epithelium detachment in treatment-resistant macular neovascularization: an OCT and AI analysis

Scientific Reports
Macular neovascularization (MNV) in age-related macular degeneration (AMD) remains a therapeutic challenge, especially in eyes resistant to conventional anti-VEGF therapy.
Ines D. Nagel, Melanie D. Tran, Haochen Zhang, Lingyun Cheng, Anna Heinke, Nehal N. Mehta, Dirk-Uwe Bartsch, Fritz G. P. Kalaw, Mohamed Morsy, Arthur J. Mueller, William R. Freeman   +10 more
doaj   +1 more source